Ascletis doses first subject in Phase I solid tumour trial
According to the preclinical studies, ASC61 demonstrated having good safety and pharmacokinetic profiles in animal models.
Oncology
Latest in
Oncology
BCAN reveals award worth $3m to boost bladder cancer research
The funding will support translational research and trials and will have a quick impact on bladder cancer therapies.
Jubilant receives FDA IND clearance for Phase I/II solid tumour trial
The two-part trial will analyse the safety, pharmacokinetics, optimal dosing and initial activity of JBI-778.
Antengene doses first subject in Phase I cancer trial
To be carried out at four centres in China, the trial will have dose-escalation and dose-expansion portions.
Roche’s subcutaneous Tecentriq meets Phase III NSCLC co-primary endpoints
In the trial, Tecentriq’s subcutaneous formulation safety profile was in line with that of IV Tecentriq.
Tavanta concludes subject enrolment in Phase III prostate cancer trial
The company anticipates topline data from the trial in the fourth quarter of this year.
Hutchmed begins dosing in follicular lymphoma therapy trial in China
The Phase II bridging study will assess the safety, pharmacokinetics, and efficacy of tazemetostat to treat R/R FL patients.
Turning cold tumours hot: increasing immune checkpoint inhibitor response rates
Companies are exploring ways to increase tumour visibility so more patients benefit from immune checkpoint inhibitor therapy.
By